Moloney Securities Asset Management LLC Purchases 1,028 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Moloney Securities Asset Management LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 40.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,547 shares of the medical research company's stock after buying an additional 1,028 shares during the period. Moloney Securities Asset Management LLC's holdings in Thermo Fisher Scientific were worth $1,765,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth about $25,000. Ameriflex Group Inc. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $30,000. Cassady Schiller Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 89.2% in the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock valued at $36,000 after acquiring an additional 33 shares during the period. VSM Wealth Advisory LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $36,000. Finally, Navigoe LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of analyst reports. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Scotiabank cut their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research report on Friday, April 25th. Stifel Nicolaus dropped their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. UBS Group lowered shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and dropped their target price for the company from $500.00 to $460.00 in a research report on Tuesday. Finally, Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $601.05.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Up 3.0%

Shares of NYSE TMO traded up $12.45 during mid-day trading on Thursday, hitting $432.33. The stock had a trading volume of 1,487,913 shares, compared to its average volume of 1,985,532. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The business has a 50 day moving average price of $408.93 and a two-hundred day moving average price of $477.89. The firm has a market cap of $163.20 billion, a P/E ratio of 25.35, a price-to-earnings-growth ratio of 2.27 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The firm's revenue for the quarter was up .2% on a year-over-year basis. During the same period in the previous year, the firm earned $5.11 earnings per share. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.